

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

Matt S. Anderson¹ · Sauzanne Khalilieh¹ · Ka Lai Yee¹ · Rachael Liu¹ ·
Li Fan¹ · Matthew L. Rizk¹ · Vedangi Shah¹ · Azra Hussaini² · Ivy Song³ ·
Lisa L. Ross⁴ · Joan R. Butters¹

Published online: 10 February 2017
© Springer International Publishing Switzerland 2017

Erratum to: Clin Pharmacokinet
DOI 10.1007/s40262-016-0458-4

Figures 2 and 3, and their corresponding legends were incorrect and were corrected in this erratum.

Figures 2 and 3 should appear as follows:

The online version of the original article can be found under
doi:[10.1007/s40262-016-0458-4](https://doi.org/10.1007/s40262-016-0458-4).

✉ Matt S. Anderson
matt_anderson@merck.com

¹ Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA

² PAREXEL, Baltimore, MD, USA

³ GlaxoSmithKline, Research Triangle Park, NC, USA

⁴ ViiV Healthcare, Research Triangle Park, NC, USA

Fig. 2 Individual analyte parameter ratios for dolutegravir (a) and doravirine (b) with geometric mean ratios and 90% confidence intervals following multiple-dose administration with and without the additional treatment [doravirine and dolutegravir, respectively (per-protocol population)]. AUC_{0-24} area under the plasma concentration–time curve from dosing to 24 h post-dose, C_{24} concentration 24 h post-dose, C_{max} maximum concentration




Fig. 3 Arithmetic mean steady-state doravirine plasma concentration profile with and without co-administration with dolutegravir: **a** linear scale (\pm SD) and **b** semi-log scale, *SD* standard deviation

